{"id":"placebo-for-ipatasertib","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebo is an inert substance used as a control in clinical trials to establish the efficacy of the active drug (ipatasertib, an AKT inhibitor) through comparison. It allows researchers to distinguish true drug effects from natural disease progression and psychological effects.","oneSentence":"This is a placebo control and has no active pharmacological mechanism.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:27:15.708Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Control arm in ipatasertib clinical trials (specific indication depends on the trial protocol)"}]},"trialDetails":[{"nctId":"NCT04650581","phase":"PHASE3","title":"Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor","status":"ACTIVE_NOT_RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2021-01-27","conditions":"Breast Cancer","enrollment":250},{"nctId":"NCT04177108","phase":"PHASE3","title":"A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2019-11-25","conditions":"Triple-Negative Breast Cancer","enrollment":242},{"nctId":"NCT03337724","phase":"PHASE3","title":"A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2018-01-06","conditions":"Breast Cancer","enrollment":579},{"nctId":"NCT01485861","phase":"PHASE1, PHASE2","title":"Study of Ipatasertib or Apitolisib With Abiraterone Acetate Versus Abiraterone Acetate in Participants With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2012-01-11","conditions":"Prostate Cancer","enrollment":298},{"nctId":"NCT01896531","phase":"PHASE2","title":"A Study of Ipatasertib (GDC-0068) in Combination With Fluoropyrimidine Plus Oxaliplatin in Participants With Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2013-08-14","conditions":"Gastric Cancer","enrollment":153},{"nctId":"NCT02162719","phase":"PHASE2","title":"A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2014-08-19","conditions":"Breast Neoplasms","enrollment":124},{"nctId":"NCT02301988","phase":"PHASE2","title":"A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Neoadjuvant Treatment for Participants With Early Stage Triple Negative Breast Cancer","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2015-02-17","conditions":"Breast Cancer","enrollment":151}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":15,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo for Ipatasertib","genericName":"Placebo for Ipatasertib","companyName":"Hoffmann-La Roche","companyId":"roche","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a placebo control and has no active pharmacological mechanism. Used for Control arm in ipatasertib clinical trials (specific indication depends on the trial protocol).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}